Products Filgrastim is commercially available as a solution for injection in vials and prefilled syringes (Neupogen, biosimilars). It has been approved in many countries since 1991. Structure and properties Filgrastim is a protein of 175 amino acids produced by biotechnology. The sequence corresponds to human granulocyte colony-stimulating factor (G-CSF, Mr = 18,800 Da) with the … Filgrastim
Products Pegfilgrastim is commercially available as a solution for injection in the form of prefilled syringes (Neulasta). It has been approved in many countries since 2003. Biosimilars have been approved. Structure and properties Pegfilgrastim is a conjugate of filgrastim with a single 20-kDa polyethylene glycol (PEG) molecule. Filgrastim is a protein of 175 amino acids … Pegfilgrastim
Products Lenograstim is commercially available as an injection/infusion preparation (Granocyte). It has been approved in many countries since 1993. Structure and properties Lenograstim is a protein of 174 amino acids produced by biotechnology. The sequence corresponds to human granulocyte colony-stimulating factor (G-CSF). Unlike filgrastim, lenograstim is identical to G-CSF and is glycosylated. Effects Lenograstim (ATC … Lenograstim
Products Mifamurtide is commercially available as a powder for a concentrate for the preparation of an infusion dispersion (Mepact). It was approved in the EU in 2009 and in many countries in 2010. It was originally developed in the early 1980s at Ciba-Geigy. Structure and properties Mifamurtide (L-MTP-PE) is a fully synthetic derivative of muramyl … Mifamurtid
